# US 2023/0065895 A1 · Poxviral-based vaccine against severe acute respiratory syndrome coronavirus 2 and methods using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065895 A1
- Document ID: US20230065895A1
- Status: Published application
- Kind: A1
- Application number: 17/870,070
- Filed: 2022-07-21
- Published: 2023-03-02
- Earliest claimed: 2021-07-21
- Assignees: Academia Sinica
- Applicants: Academia Sinica
- Inventors: Wen Chang; Rakesh Kulkarni; Shiu-Lok Hu
- Web page: https://patentgrep.com/patent/US20230065895A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/14: for RNA viruses
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a recombinant poxviral vector for use in vaccinating a subject against SARS-CoV-2. The present invention also provides vaccination regimens using the recombinant poxviral vector, which confers protective immunity against SARS-CoV-2.

## Claims

### Claim 1

A recombinant poxviral vector which comprises a polynucleotide encoding a SARS-CoV-2 spike protein in a poxviral vector for use in vaccinating a subject against SARS-CoV-2.

### Claim 2 (depends on 1)

The recombinant poxviral vector of claim 1, wherein the poxviral vector is an orthopox viral vector.

### Claim 3 (depends on 2)

The recombinant poxviral vector of claim 2, wherein the orthopox viral vector is selected from the group consisting of a camelpox viral vector, a cowpox viral vector, a monkey pox viral vector, a smallpox viral vector and a vaccinia vial vector.

### Claim 4 (depends on 3)

The recombinant poxviral vector of claim 3, wherein the vaccinia vial vector is modified vaccine Ankara (MVA) or v-NY.

### Claim 5 (depends on 1)

The recombinant poxviral vector of claim 1, wherein the recombinant poxviral vector lacks a functional thymidine kinase gene.

### Claim 6 (depends on 1)

The recombinant poxviral vector of claim 1, wherein the polynucleotide is operatively-linked to a promoter.

### Claim 7 (depends on 6)

The recombinant poxviral vector of claim 6, wherein the promoter is a poxviral promoter.

### Claim 8 (depends on 7)

The recombinant poxviral vector of claim 7, wherein the promoter is a vaccinia viral early and late dual promoter.

### Claim 9 (depends on 1)

The recombinant poxviral vector of claim 1, wherein the SARS-CoV-2 spike protein comprises the amino acid sequence of SEQ ID NO: 1, 2, 3, 4 or 5, or a functional variant thereof.

### Claim 10 (depends on 1)

The recombinant poxviral vector of claim 1, which is v-NY-S (deposit accession number BCRC970077 or CNCM 1-5857).

### Claim 11

An immunogenic composition against SARS-CoV-2 which comprises an effective amount of a recombinant poxviral vector and a physiologically acceptable vehicle, wherein the recombinant poxviral vector comprises a polynucleotide encoding a SARS-CoV-2 spike protein in a poxviral vector.

### Claim 12 (depends on 11)

The immunogenic composition of claim 11, which further comprises an adjuvant.

### Claim 13 (depends on 11)

The immunogenic composition of claim 11, wherein the recombinant poxviral vector is v-NY-S (deposit accession number BCRC970077 or CNCM I-5857).

### Claim 14

A method for vaccinating a subject against SARS-CoV-2, comprising administering to the subject an effective amount of a recombinant poxviral vector or an immunogenic composition comprising the recombinant poxviral vector, wherein the recombinant poxviral vector comprises a polynucleotide encoding a SARS-CoV-2 spike protein in a poxviral vector.

### Claim 15 (depends on 14)

The method of claim 14, wherein the recombinant poxviral vector or the immunogenic composition is administered via a route selected from the group consisting of intramuscular injection, subcutaneous injection, intranasal administration, intradermal injection, skin scarification and oral administration and any combination thereof.

### Claim 16 (depends on 14)

The method of claim 14, wherein the recombinant poxviral vector or the immunogenic composition is administered to the subject once or more than once.

### Claim 17 (depends on 14)

The method of claim 14, comprising a first administration, followed by a second administration, of the recombinant poxviral vector or the immunogenic composition.

### Claim 18 (depends on 17)

The method of claim 17, wherein the first administration and the second administration are intramuscular injection.

### Claim 19 (depends on 17)

The method of claim 17, wherein the first administration is skin scarification and the second administration is intramuscular injection.

### Claim 20 (depends on 17)

The method of claim 17, wherein the second administration is about four weeks after the first administration.

### Claim 21 (depends on 17)

The method of any of claims 17, wherein the same dose is given in the first administration and the second administration.

### Claim 22 (depends on 17)

The method of any of claims 17, wherein a higher dose is given in the first administration than in the second administration.

### Claim 23 (depends on 14)

The method of claim 14, wherein the recombinant poxviral vector comprises v-NY-S and/or MVA-S.

### Claim 24 (depends on 23)

The method of claim 23, comprising administering an effective amount of v-NY-S first and administering an effective amount of MVA-S later to the subject.

### Claim 25 (depends on 24)

The method of claim 24, wherein v-NY-S is administered via skin scarification and MVA-S is administered via intramuscular injection.

### Claim 26 (depends on 23)

The method of claim 23, comprising administering a first amount of v-NY-S first via skin scarification and administering a second amount of MVA-S via intramuscular injection after at least four weeks of the administration of v-NY-S to the subject, wherein the second amount is higher than the first amount.

### Claim 27 (depends on 14)

The method of claim 14, wherein the method is effective in inducing neutralizing antibodies and specific TH1-biased immune responses and effector memory CD8+ T cells ragainst SARS-CoV-2 in the subject.

### Claim 28 (depends on 14)

The method of claim 14, wherein the method is effective in reducing a disease or condition caused by SARS-CoV-2 infection in the subject.

### Claim 29 (depends on 28)

The method of claim 28, wherein the disease or condition includes damages in organs or tissues in the subject, selected from the group consisting of lung, gastrointestinal tract, heart, kidney, liver, adrenal glands and/or testis.

### Claim 30 (depends on 28)

The method of claim 28, wherein the disease or condition includes a pathological condition in lung, selected from the group consisting of diffuse congestion, shrinking of alveoli, hemorrhaging, immune cell infiltration and any combination thereof.
